Marksans Pharma to acquire 100% of Netherlands-based QliniQ B.V. for 7.5 million euros

Listed Co AcquisitionStrategic Transactions View source PDF Explain this filing

MARKSANS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.5%Reaction day

₹245.80

prior close

₹249.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-1.1%-0.4% vs market

Pharmaceuticals peers, median of 164sector-0.6%-0.9% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+1.2

15m

+0.2

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.5-1.1-0.4-0.6-0.9

Next day

-1.5-0.0-1.5-1.0-0.6

-1.2+0.2-1.4-1.0-0.2

-2.8+1.1-3.8-0.8-1.9

-5.0+1.1-6.1-0.7-4.3

-4.0-0.9-3.1-1.5-2.5

+0.9-0.5+1.4-1.3+2.2

15d

+4.4+7.1-2.7+2.7+1.6

+9.1+6.5+2.6+3.8+5.3

+6.7+7.9-1.2+4.6+2.1

+31.3+11.2+20.1+5.9+25.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Marksans Pharma will acquire 100% of Netherlands-based QliniQ B.V. for 7.5 million euros in cash, expected to close by June 15, 2026. QliniQ is a profitable pharma distribution company with FY2025 revenue of 9.35 million euros, net profit of 1.01 million euros, and 41 percent revenue CAGR from FY2023 to FY2025. It is debt-free. The deal gives Marksans direct market access in the Netherlands and strengthens its presence in regulated European markets.

Likely market impact

Strategic European expansion with direct market access. Deal size is small versus Marksans' Rs 3,033 cr total income, so limited near-term impact.